Lead Product(s): Sarconeos
Therapeutic Area: Infections and Infectious Diseases Product Name: BIO101
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2021
The Company receives a favorable opinion from the DMC on the safety of Sarconeos (BIO101) in the COVA study following first interim analysis. Patient enrollment has now reached 97 of the 155 planned for the second interim analysis.